Revenue trends for Kyprolis
In 4Q17, Amgen’s (AMGN) Kyprolis generated revenues of $227 million, which reflected a 24% growth on a YoY (year-over-year) basis and a 10% growth quarter-over-quarter. In 4Q17 in the US markets and international markets, Kyprolis generated revenues of $150 million and $77 million, respectively.
In fiscal 2017, Kyprolis had revenues of $835 million, which reflected a 21% growth YoY. In 2017 in the US and international markets, Kyprolis had revenues of $562 million and $273 million, respectively.
In January 2018, the EMA’s (European Medicines Agency) CHMP (Committee for Medicinal Products for Human Use) recommended a positive opinion for label expansion of Amgen’s Kyprolis. It recommended to include updated data on overall survival (or OS) generated from the Phase 3 head-to-head ENDEAVOR trial in individuals with relapsed or refractory multiple myeloma.
In the ENDEAVOR trial, a combination therapy of Kyprolis and dexamethasone demonstrated a reduction in the risk of death by 21% compared to Takeda Pharmaceuticals’ combination therapy of Velcade and dexamethasone. The ENDEAVOR trial also demonstrated an increase in OS by 7.6 months with the Kyprolis and dexamethasone combination therapy compared to the Velcade and dexamethasone combination therapy.
In January 2017, the FDA (U.S. Food & Drug Administration) approved the label expansion of Kyprolis to include the updated data from the ENDEAVOR trial.
The label expansion of Kyprolis is expected to further strengthen the commercialization capabilities of the drug. To know more about Kyprolis, please refer to Kyprolis Could Boost Amgen’s Revenue Growth in 2018.
The American Cancer Society estimates 30,770 new cases of multiple myeloma and 12,770 deaths due to multiple myeloma in 2018 in the United States. According to Globocan, 114,000 individuals are diagnosed with multiple myeloma every year worldwide. The statistics from the American Cancer Society and Globocan show the large multiple myeloma population in the United States and worldwide.